Product news from the 02/13/07 news brief

Share this article:
Pfizer said the FDA has approved new labeling of Sutent (sunitinib malate) which includes first-line treatment of advanced renal cell carcinoma, a type of advanced kidney cancer, based on results of a large Phase III trial, which showed prolonged progression-free survival. Mylan Laboratories and Barr Pharmaceuticals became the second and third drugmakers to receive FDA approval to sell generic versions of Pfizer’s blockbuster antidepressant Zoloft (sertraline). Both companies said they would begin shipping the product immediately. Pfizer lost patent protection on Zoloft last August. Branded Zoloft sales fell 79% in Pfizer’s fourth quarter to $166 million, compared with $808 million in the same period a year earlier. Teva Pharmaceutical was able to sell the only generic version during the first six months after expiration of Zoloft’s patent, under a federally enforced exclusivity period.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.